Towards optimising experimental quantification of persistent pain in Parkinson’s disease using psychophysical testing

Abstract People with Parkinson’s disease (PD) may live for multiple decades after diagnosis. Ensuring that effective healthcare provision is received across the range of symptoms experienced is vital to the individual’s wellbeing and quality of life. As well as the hallmark motor symptoms, PD patien...

Full description

Bibliographic Details
Main Authors: Kirsty Bannister, Rory V. Smith, Patrick Wilkins, Tatum M. Cummins
Format: Article
Language:English
Published: Nature Publishing Group 2021-03-01
Series:npj Parkinson's Disease
Online Access:https://doi.org/10.1038/s41531-021-00173-y
id doaj-6eff7ffbf1af4eb28ddb9cb7c3b39ea1
record_format Article
spelling doaj-6eff7ffbf1af4eb28ddb9cb7c3b39ea12021-03-21T12:52:50ZengNature Publishing Groupnpj Parkinson's Disease2373-80572021-03-01711710.1038/s41531-021-00173-yTowards optimising experimental quantification of persistent pain in Parkinson’s disease using psychophysical testingKirsty Bannister0Rory V. Smith1Patrick Wilkins2Tatum M. Cummins3Central Modulation of Pain, Institute of Psychiatry, Psychology and Neuroscience, King’s College LondonCentral Modulation of Pain, Institute of Psychiatry, Psychology and Neuroscience, King’s College LondonCentral Modulation of Pain, Institute of Psychiatry, Psychology and Neuroscience, King’s College LondonCentral Modulation of Pain, Institute of Psychiatry, Psychology and Neuroscience, King’s College LondonAbstract People with Parkinson’s disease (PD) may live for multiple decades after diagnosis. Ensuring that effective healthcare provision is received across the range of symptoms experienced is vital to the individual’s wellbeing and quality of life. As well as the hallmark motor symptoms, PD patients may also suffer from non-motor symptoms including persistent pain. This type of pain (lasting more than 3 months) is inconsistently described and poorly understood, resulting in limited treatment options. Evidence-based pain remedies are coming to the fore but therapeutic strategies that offer an improved analgesic profile remain an unmet clinical need. Since the ability to establish a link between the neurodegenerative changes that underlie PD and those that underlie maladaptive pain processing leading to persistent pain could illuminate mechanisms or risk factors of disease initiation, progression and maintenance, we evaluated the latest research literature seeking to identify causal factors underlying persistent pain in PD through experimental quantification. The majority of previous studies aimed to identify neurobiological alterations that could provide a biomarker for pain/pain phenotype, in PD cohorts. However heterogeneity of patient cohorts, result outcomes and methodology between human psychophysics studies overwhelmingly leads to inconclusive and equivocal evidence. Here we discuss refinement of pain-PD paradigms in order that future studies may enhance confidence in the validity of observed effect sizes while also aiding comparability through standardisation. Encouragingly, as the field moves towards cross-study comparison of data in order to more reliably reveal mechanisms underlying dysfunctional pain processing, the potential for better-targeted treatment and management is high.https://doi.org/10.1038/s41531-021-00173-y
collection DOAJ
language English
format Article
sources DOAJ
author Kirsty Bannister
Rory V. Smith
Patrick Wilkins
Tatum M. Cummins
spellingShingle Kirsty Bannister
Rory V. Smith
Patrick Wilkins
Tatum M. Cummins
Towards optimising experimental quantification of persistent pain in Parkinson’s disease using psychophysical testing
npj Parkinson's Disease
author_facet Kirsty Bannister
Rory V. Smith
Patrick Wilkins
Tatum M. Cummins
author_sort Kirsty Bannister
title Towards optimising experimental quantification of persistent pain in Parkinson’s disease using psychophysical testing
title_short Towards optimising experimental quantification of persistent pain in Parkinson’s disease using psychophysical testing
title_full Towards optimising experimental quantification of persistent pain in Parkinson’s disease using psychophysical testing
title_fullStr Towards optimising experimental quantification of persistent pain in Parkinson’s disease using psychophysical testing
title_full_unstemmed Towards optimising experimental quantification of persistent pain in Parkinson’s disease using psychophysical testing
title_sort towards optimising experimental quantification of persistent pain in parkinson’s disease using psychophysical testing
publisher Nature Publishing Group
series npj Parkinson's Disease
issn 2373-8057
publishDate 2021-03-01
description Abstract People with Parkinson’s disease (PD) may live for multiple decades after diagnosis. Ensuring that effective healthcare provision is received across the range of symptoms experienced is vital to the individual’s wellbeing and quality of life. As well as the hallmark motor symptoms, PD patients may also suffer from non-motor symptoms including persistent pain. This type of pain (lasting more than 3 months) is inconsistently described and poorly understood, resulting in limited treatment options. Evidence-based pain remedies are coming to the fore but therapeutic strategies that offer an improved analgesic profile remain an unmet clinical need. Since the ability to establish a link between the neurodegenerative changes that underlie PD and those that underlie maladaptive pain processing leading to persistent pain could illuminate mechanisms or risk factors of disease initiation, progression and maintenance, we evaluated the latest research literature seeking to identify causal factors underlying persistent pain in PD through experimental quantification. The majority of previous studies aimed to identify neurobiological alterations that could provide a biomarker for pain/pain phenotype, in PD cohorts. However heterogeneity of patient cohorts, result outcomes and methodology between human psychophysics studies overwhelmingly leads to inconclusive and equivocal evidence. Here we discuss refinement of pain-PD paradigms in order that future studies may enhance confidence in the validity of observed effect sizes while also aiding comparability through standardisation. Encouragingly, as the field moves towards cross-study comparison of data in order to more reliably reveal mechanisms underlying dysfunctional pain processing, the potential for better-targeted treatment and management is high.
url https://doi.org/10.1038/s41531-021-00173-y
work_keys_str_mv AT kirstybannister towardsoptimisingexperimentalquantificationofpersistentpaininparkinsonsdiseaseusingpsychophysicaltesting
AT roryvsmith towardsoptimisingexperimentalquantificationofpersistentpaininparkinsonsdiseaseusingpsychophysicaltesting
AT patrickwilkins towardsoptimisingexperimentalquantificationofpersistentpaininparkinsonsdiseaseusingpsychophysicaltesting
AT tatummcummins towardsoptimisingexperimentalquantificationofpersistentpaininparkinsonsdiseaseusingpsychophysicaltesting
_version_ 1724210070991929344